[CIMB] YoY Cumulative Quarter Result on 31-Dec-2021 [#4]

Announcement Date
28-Feb-2022
Admission Sponsor
-
Sponsor
-
Financial Year
31-Dec-2021
Quarter
31-Dec-2021 [#4]
Profit Trend
QoQ- 24.83%
YoY- 259.62%
View:
Show?
Cumulative Result
31/12/23 31/12/22 31/12/21 31/12/20 31/12/19 31/12/18 31/12/17 CAGR
Revenue 21,014,482 19,837,516 19,512,940 17,189,003 17,795,879 17,381,968 17,626,496 2.97%
PBT 9,540,731 8,371,010 5,789,478 1,530,329 5,974,840 7,200,667 6,109,985 7.70%
Tax -2,378,636 -2,778,079 -1,396,853 -383,760 -1,519,653 -1,537,314 -1,502,019 7.95%
NP 7,162,095 5,592,931 4,392,625 1,146,569 4,455,187 5,663,353 4,607,966 7.62%
-
NP to SH 6,980,962 5,439,863 4,295,334 1,194,424 4,559,656 5,583,510 4,475,175 7.68%
-
Tax Rate 24.93% 33.19% 24.13% 25.08% 25.43% 21.35% 24.58% -
Total Cost 13,852,387 14,244,585 15,120,315 16,042,434 13,340,692 11,718,615 13,018,530 1.03%
-
Net Worth 68,327,042 62,114,290 58,500,021 55,925,837 55,791,709 51,096,139 47,841,687 6.11%
Dividend
31/12/23 31/12/22 31/12/21 31/12/20 31/12/19 31/12/18 31/12/17 CAGR
Div 4,585,993 2,756,206 2,335,409 477,294 2,559,523 2,378,157 2,287,062 12.28%
Div Payout % 65.69% 50.67% 54.37% 39.96% 56.13% 42.59% 51.11% -
Equity
31/12/23 31/12/22 31/12/21 31/12/20 31/12/19 31/12/18 31/12/17 CAGR
Net Worth 68,327,042 62,114,290 58,500,021 55,925,837 55,791,709 51,096,139 47,841,687 6.11%
NOSH 10,665,106 10,665,106 10,221,456 9,922,971 9,922,971 9,564,459 9,225,547 2.44%
Ratio Analysis
31/12/23 31/12/22 31/12/21 31/12/20 31/12/19 31/12/18 31/12/17 CAGR
NP Margin 34.08% 28.19% 22.51% 6.67% 25.03% 32.58% 26.14% -
ROE 10.22% 8.76% 7.34% 2.14% 8.17% 10.93% 9.35% -
Per Share
31/12/23 31/12/22 31/12/21 31/12/20 31/12/19 31/12/18 31/12/17 CAGR
RPS 197.04 187.13 192.09 173.22 180.77 182.73 192.68 0.37%
EPS 65.46 52.18 42.86 12.04 46.98 59.67 49.63 4.71%
DPS 43.00 26.00 22.99 4.81 26.00 25.00 25.00 9.45%
NAPS 6.4066 5.8594 5.7588 5.636 5.6674 5.3714 5.2296 3.43%
Adjusted Per Share Value based on latest NOSH - 10,221,456
31/12/23 31/12/22 31/12/21 31/12/20 31/12/19 31/12/18 31/12/17 CAGR
RPS 196.04 185.06 182.03 160.35 166.01 162.15 164.43 2.97%
EPS 65.12 50.75 40.07 11.14 42.54 52.09 41.75 7.68%
DPS 42.78 25.71 21.79 4.45 23.88 22.19 21.34 12.28%
NAPS 6.3741 5.7945 5.4574 5.2172 5.2047 4.7667 4.4631 6.11%
Price Multiplier on Financial Quarter End Date
31/12/23 31/12/22 31/12/21 31/12/20 31/12/19 31/12/18 31/12/17 CAGR
Date 29/12/23 30/12/22 31/12/21 31/12/20 31/12/19 31/12/18 29/12/17 -
Price 5.85 5.80 5.45 4.30 5.15 5.71 6.54 -
P/RPS 2.97 3.10 2.84 2.48 2.85 3.12 3.39 -2.17%
P/EPS 8.94 11.30 12.89 35.72 11.12 9.73 13.37 -6.48%
EY 11.19 8.85 7.76 2.80 8.99 10.28 7.48 6.94%
DY 7.35 4.48 4.22 1.12 5.05 4.38 3.82 11.51%
P/NAPS 0.91 0.99 0.95 0.76 0.91 1.06 1.25 -5.15%
Price Multiplier on Announcement Date
31/12/23 31/12/22 31/12/21 31/12/20 31/12/19 31/12/18 31/12/17 CAGR
Date 29/02/24 28/02/23 28/02/22 26/02/21 28/02/20 28/02/19 28/02/18 -
Price 6.46 5.61 5.71 4.33 4.82 5.85 7.19 -
P/RPS 3.28 3.00 2.97 2.50 2.67 3.20 3.73 -2.11%
P/EPS 9.87 10.93 13.50 35.97 10.41 9.97 14.70 -6.42%
EY 10.13 9.15 7.41 2.78 9.61 10.03 6.80 6.86%
DY 6.66 4.63 4.03 1.11 5.39 4.27 3.48 11.41%
P/NAPS 1.01 0.96 0.99 0.77 0.85 1.09 1.37 -4.95%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.

NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ & YoY figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment